1. The challenges of handling deferasirox in sickle cell disease patients older than 40 years
- Author
-
Eliane Alves Soares, Fernando Ferreira Costa, Lorena Bedotti Ribeiro, Simone Cristina Olenscki Gilli, Sara Teresinha Olalla Saad, and Bruno Deltreggia Benites
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cell ,Anemia, Sickle Cell ,Disease ,Iron Chelating Agents ,Nephrotoxicity ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Hemochromatosis ,Aged ,Iron Chelator ,business.industry ,Deferasirox ,Hematology ,Iron chelation therapy ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Toxicity ,Female ,business ,030215 immunology ,medicine.drug - Abstract
Deferasirox is an oral iron chelator with established dose-dependent efficacy for the treatment of iron overload secondary to transfusion. However, there is few data reporting the use of Desferasirox in adult patients with sickle cell disease (SCD) and transfusional iron overload.We conducted a prospective, single center, nonrandomized study from January 2014 to March 2015 in Campinas, Brazil. Seven patients (five women, median age 50 y.o.) who were followed up on regular transfusion program were treated with a single daily dose of deferasirox (median dose 20 mg/kg). They were monitored for clinical symptoms, renal function and hepatotoxicity.One patient discontinued the study due to lack of compliance. Two patients reported mild to moderate adverse events (gastrointestinal disturbances). Five patients had the drug discontinued due to worsening of renal function. One patient had the drug discontinued due to severe hepatotoxicity that evolved to death; no patient finished the study.
- Published
- 2019